Myelodysplastic syndromes.

Publication Type:

Journal Article

Source:

Annual review of medicine, Volume 61, p.345-58 (2010)

Keywords:

2010, Antineoplastic Agents, Center-Authored Paper, Clinical Research Division, hematopoietic stem cell transplantation, Humans, Myelodysplastic Syndromes, Prognosis, Survival Rate

Abstract:

Myelodysplastic syndromes (MDS) represent a collection of stem cell disorders characterized by impaired hematopoiesis resulting in low peripheral blood counts. The majority of patients with MDS present with symptoms related to anemia; however, bleeding and infection are the most common causes of death. The median age of diagnosis is 72 and the median survival is 2.5 years. Lenalidomide, azacitidine, and decitabine are all FDA-approved agents to treat MDS; however, the only potential cure for MDS remains stem cell transplantation.